Rolf M. Zinkernagel
Founder at Hookipa Biotech AG
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Hans Jörg Reinhardt | M | 68 | 40 years | |
| Bill Winters | M | 62 | 11 years | |
| Vasant Narasimhan | M | 48 | 19 years | |
| Charles Sawyers | M | 65 | 11 years | |
| Samir Shah | M | 63 | 20 years | |
| Charlotte Pamer-Wieser | M | - | 13 years | |
| Heidi Feik | F | - |
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
| Vera Strasser | F | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
| Franz Heinz | M | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
| Arnaud Marchant | M | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
| Gregor Zünd | M | 65 |
University of Zurich
| 20 years |
| Lukas Flatz | M | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 13 years |
| Andreas Bergthaler | M | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 13 years |
| Paul-Henri Lambert | M | 85 |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
| Harry Werner Kirsch | M | 59 | 21 years | |
| Frank Kalkbrenner | M | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 11 years |
| Daniel D. Pinschewer | M | 49 |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 13 years |
| Michael Kelly | M | 67 |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 5 years |
| Urs F. Greber | M | - |
University of Zurich
| 21 years |
| Hans Wehrli | M | 71 |
University of Zurich
| 31 years |
| Graziano Seghezzi | M | 55 |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
| Hans Caspar von der Crone | M | 67 |
University of Zurich
| 27 years |
| Sander J. van Deventer | M | 69 |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
| Graeme Martin | M | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
| Linda Armstrong | M | 61 | 17 years | |
| Markus Hosang | M | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
| Andreas Plückthun | M | 65 |
University of Zurich
| 31 years |
| Jan van de Winkel | M | 63 |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 7 years |
| Jörn Aldag | M | 65 |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 8 years |
| Simon Brown | M | - | 11 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Joseph Jimenez | M | 64 | 11 years | |
| Ulrich Lehner | M | 78 | 13 years | |
| Wendelin Wiedeking | M | 72 | 11 years | |
| Ronen Tamir | M | 57 | - | |
| Giancarlo Mocchi | M | 84 | 3 years | |
| Gary Sutton | M | - | 13 years | |
| Dimitri Azar | M | 65 | 7 years | |
| Juan Andres | M | 59 | 12 years | |
| Susanne Antonie Schaffert | M | 57 | 2 years | |
| Enrico Cipro Vanni | M | 73 | - | |
| Alexander Tobler | M | - |
University of Zurich
| 6 years |
| Teodoro D. Cocca | M | 51 |
University of Zurich
| 7 years |
| Dirk van de Put | M | 63 | 1 years | |
| Katherine Cohen | M | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 5 years |
| Daniel Anders | M | 54 |
University of Zurich
| 7 years |
| Judith Bischof | M | 50 |
University of Zurich
| 6 years |
| Verena A. Briner | M | 72 | 3 years | |
| Iris Bohnet Zürcher | M | 58 |
University of Zurich
| 5 years |
| Peter Maag | M | 57 | 5 years | |
| Thomas Meier | M | - |
University of Zurich
| 6 years |
| Oliver Hofmann | M | 53 |
University of Zurich
| 6 years |
| Philippe Bertschi | M | - |
University of Zurich
| 6 years |
| Philippe Weber | M | 59 |
University of Zurich
| 5 years |
| David Schmid | M | 42 |
University of Zurich
| 5 years |
| Michel Fellmann | M | - |
University of Zurich
| 6 years |
| Mariel Hoch | M | 51 |
University of Zurich
| 14 years |
| Rene Dittrich | M | 52 |
University of Zurich
| 6 years |
| Georgette Schmid | F | - |
University of Zurich
| 6 years |
| Marc Weber | M | 53 |
University of Zurich
| 7 years |
| Simon Lamprecht | M | 51 |
University of Zurich
| 3 years |
| Kim Stratton | F | 62 | 3 years | |
| Sandra Nadine Ramsauer | M | - |
University of Zurich
| 14 years |
| Cédric Perlet | M | - |
University of Zurich
| 7 years |
| Srikant T. Madhav Datar | M | 70 | 18 years | |
| Jürgen Brokatzky-Geiger | M | 72 | 14 years | |
| Andreas von Planta | M | 68 | - | |
| Daniel Schmucki | M | 56 |
University of Zurich
| 6 years |
| Alexandre F. Jetzer-Chung | M | 83 | 15 years | |
| Daniel Vasella | M | 70 | 17 years | |
| Thomas Roland Meier | M | 61 |
University of Zurich
| 4 years |
| Thomas Wellauer | M | 69 | - | |
| Dominik Escher | M | - |
University of Zurich
| 8 years |
| William Brody | M | 80 | - | |
| Ann Marie Fudge | F | 72 | - | |
| Mun Tak Yang | F | 70 | - | |
| Shannon Klinger | M | 53 | 10 years | |
| Michael Sidler | M | 55 |
University of Zurich
| 8 years |
| Reto Suter | M | 53 |
University of Zurich
| 8 years |
| Ian Garland | M | 59 | - | |
| Sanjay Shukla | M | 52 | 3 years | |
| George Gunn | M | 74 | 12 years | |
| Gina Massa Mias | F | - | - | |
| Muriel Cottard | M | - | 14 years | |
| Ramon Mohanlal | M | 65 | 3 years | |
| Sierk Poetting | M | 51 | 2 years | |
| Paolo Baroldi | M | 73 | 4 years | |
| Ueli Roost | M | 76 |
University of Basel
| 4 years |
| Mihael Polymeropoulos | M | 64 | 5 years | |
| Adrian Widmer | M | 56 |
University of Zurich
| 6 years |
| Brian McNamara | M | 57 | - | |
| Lijin Aryananda | M | - |
University of Zurich
| 4 years |
| Anne-Françoise Viollier | M | - |
University of Basel
| 4 years |
| Atul Khosia | M | - | - | |
| Beth Calitri | F | - | 8 years | |
| Rudolf Marty | M | 75 |
University of Zurich
| 10 years |
| Johannes Suter | M | - |
University of Zurich
| 5 years |
| Fredrik Ollila | M | - | - | |
| Frank Palantoni | M | 66 | 6 years | |
| Haleh Brönner | M | 55 |
University of Zurich
| 6 years |
| Hans Ulrich Maerki | M | 76 |
University of Basel
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 83 | 83.00% |
| Austria | 17 | 17.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Rolf M. Zinkernagel
- Personal Network
